We are live on ! Find out more
FPRX

Five Prime Therapeutics, Inc.
FPRX

Delisted

FPRX was delisted on the 15th of April, 2021.

176 hedge funds and large institutions have $1.39B invested in Five Prime Therapeutics, Inc. in 2016 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 65 increasing their positions, 65 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 13 (+2)

37% more capital invested

Capital invested by funds: $1.01B → $1.39B (+$373M)

35% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 20

4% more funds holding

Funds holding: 170176 (+6)

0% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 65

94% less call options, than puts

Call options by funds: $380K | Put options by funds: $6.85M

Holders
176
Holders Change
+6
Holders Change %
+3.53%
% of All Funds
4.7%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.08%
New
27
Increased
65
Reduced
65
Closed
20
Calls
$380K
Puts
$6.85M
Net Calls
-$6.47M
Net Calls Change
-$1.55M
Name Holding Trade Value Shares
Change
Change in
Stake
N
101
Nuveen
North Carolina
$854K +$9.55K +200 +1%
Citigroup
102
Citigroup
New York
$842K +$300K +6,283 +64%
EI
103
EAM Investors
California
$825K -$248K -5,200 -25%
AIG
104
American International Group
New York
$816K +$1.1K +23 +0.1%
Allianz Asset Management
105
Allianz Asset Management
Germany
$805K -$2.45M -51,255 -77%
SCM
106
Sterling Capital Management
North Carolina
$800K +$96.6K +2,022 +15%
Schroder Investment Management Group
107
Schroder Investment Management Group
United Kingdom
$798K
FAM
108
Fred Alger Management
New York
$787K +$28.7K +600 +4%
PVI
109
Pura Vida Investments
New York
$787K +$83.6K +1,750 +13%
UBS Group
110
UBS Group
Switzerland
$782K +$625K +13,086 +726%
HMS
111
Hanseatic Management Services
New Mexico
$765K +$287 +6 +0%
DekaBank Deutsche Girozentrale
112
DekaBank Deutsche Girozentrale
Germany
$752K
CG
113
Clinton Group
New York
$746K -$530K -11,104 -44%
Royal Bank of Canada
114
Royal Bank of Canada
Ontario, Canada
$730K +$616K +12,905 +1,291%
GAM
115
Gotham Asset Management
New York
$704K -$10.9M -228,054 -94%
Neuberger Berman Group
116
Neuberger Berman Group
New York
$697K +$634K +13,276 New
Bank of America
117
Bank of America
North Carolina
$692K -$59.8K -1,253 -9%
BlackRock
118
BlackRock
New York
$653K -$16.1K -337 -3%
HI
119
HBK Investments
Texas
$651K -$2.98M -62,404 -83%
SCA
120
Secor Capital Advisors
New York
$629K +$573K +11,992 New
OC
121
Oppenheimer & Co
New York
$599K -$10.3K -215 -2%
WJA
122
Williams Jones & Associates
New York
$586K +$4.78K +100 +0.9%
MAM
123
Martingale Asset Management
Massachusetts
$586K +$533K +11,153 New
JG
124
Jefferies Group
New York
$430K -$282K -5,900 -42%
Ohio Public Employees Retirement System (OPERS)
125
Ohio Public Employees Retirement System (OPERS)
Ohio
$425K +$310K +6,494 +406%

FPRX Hedge Fund Activity: Q3 2016 in Review

176 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q3 2016, worth a combined $1.39B — up 37% from $1.01B a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new FPRX positions and 20 closed out — a net gain of 7 holders — while 65 added to existing stakes and 65 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $68.5M. The largest seller was Wellington Management Group, cutting an estimated $15.4M.

  • 176 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q3 2016, up from 170 in Q2 2016.
  • Funds reported $1.39B of Five Prime Therapeutics, Inc. stock for Q3 2016, up 37% quarter-over-quarter.
  • 27 funds opened new Five Prime Therapeutics, Inc. positions in Q3 2016 and 20 closed out, a net change of +7 holders.
  • The largest Five Prime Therapeutics, Inc. buyer in Q3 2016 was Fidelity Investments, an estimated $68.5M added.
  • The largest Five Prime Therapeutics, Inc. seller in Q3 2016 was Wellington Management Group, an estimated $15.4M sold.

Based on aggregated 13F filings for Q3 2016.